Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic therapies, centered on ONS-5010/LYTENAVA (bevacizumab gamma). The company’s business spans clinical development, regulatory approvals, manufacturing, and commercial distribution of its eye-disease product in selected international markets.

−4 736,0 %

4,0 %

−4 416,2 %

0.38

0.31

— Outlook Therapeutics, Inc.
%
Commercial ophthalmic biologic100% LYTENAVA sales to wholesalers/distributors for use in eye-care settings.
Clinical and regulatory development0% Development work for ONS-5010/LYTENAVA and related approvals.
Manufacturing and supply chain0% Contract manufacturing, fill-finish, and syringe supply for the product.

The company sells LYTENAVA to pharmaceutical wholesalers and distributors, which then supply clinics, hospitals, and...

  • Pharmaceutical wholesalers/distributorsprimary

    Buy LYTENAVA in bulk and distribute it to healthcare providers and pharmacies.

  • Clinics and hospitalsprimary

    Use the product in ophthalmology care for wet AMD patients.

  • Pharmaciessecondary

    Receive product through distribution channels for patient access.

  • Regulatory authoritiesprimary

    Approve product labeling, commercialization, and market access by geography.

Outlook Therapeutics is headquartered in Iselin, New Jersey and manufactures ONS-5010/LYTENAVA in the United States...

  • •Headquartered in Iselin, New Jersey, United States
  • •Manufacturing is performed in the United States
  • •Commercial sales have been reported in Germany and the UK
  • •European authorization supports broader international licensing efforts
  • •Southern Hemisphere markets are a stated expansion focus

The company’s strategy is to commercialize LYTENAVA in markets where it has regulatory authorization while pursuing...

01
Expand commercial access for LYTENAVAshort-term

Revenue depends on converting regulatory approvals into market sales.

02
Build partnership and licensing channelsmedium-term

Partnerships can extend geographic reach and provide funding support.

03
Secure supply chain and manufacturing capacityshort-term

Commercial execution depends on reliable cGMP manufacturing and fill-finish.

The business is exposed to financing risk, regulatory risk, and execution risk because it depends on a single...

critical

Going-concern and capital shortfall

The company needs additional financing to fund operations and commercialization.

Scope
Corporate-wide
Materiality
high
high

Regulatory approval and clinical development delays

The product depends on approvals and may require additional studies or CMC data.

Scope
ONS-5010/LYTENAVA
Materiality
high
high

Single-product concentration

Revenue and strategic value are tied largely to one ophthalmic product.

Scope
LYTENAVA
Materiality
high
high

Manufacturing and supply-chain disruption

The company relies on contract manufacturers and single-source suppliers.

Scope
Drug substance, fill-finish, syringe supply
Materiality
high
high

Intellectual property loss or challenge

Failure to secure or maintain rights could force abandonment of programs.

Scope
Product candidates and commercialization rights
Materiality
high
Revenue recognition at point of delivery
Shipment timing can shift revenue between quarters
Fair value of promissory notes
Can materially affect net income without changing cash flow
Warrant liability remeasurement
Creates non-cash earnings volatility
Going-concern and liquidity assumptions
Affects disclosure and investor assessment of survival risk

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Shuttle Pharmaceuticals Holdings, Inc.

SHPH · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

RAPT Therapeutics, Inc.

Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

: 29.4.2026